Differential uptake of estramustine phosphate metabolites and its correlation with the levels of estramustine binding protein in prostate tumor tissue

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2079-2084

  Walz, Peter H ^a   Björk, Per ^b   Gunnarsson, Per Olov ^b   Edman, Karin ^b   Hartley Asp, Beryl ^b  

^a Kreiskrankenhaus Lüdenscheid ^*  (Germany)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG BINDING PROTEIN; ESTRADIOL; ESTRAMUSTINE; ESTRAMUSTINE BINDING PROTEIN; ESTRAMUSTINE PHOSPHATE; ESTRONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG UPTAKE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROSTATE TUMOR; PROSTATECTOMY; RADIOIMMUNOASSAY;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARRIER PROTEINS; ESTRADIOL; ESTRAMUSTINE; ESTRONE; HUMANS; MALE; MIDDLE AGED; PHOSPHATES; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS;

EID: 0031719210     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Seidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. D., and Curley, T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol., 147: 931-934, 1992.
2. Hudes, G. R., Greenberg, R., Krigel, R. L., and Fox, S. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol., 10: 1754-1761, 1992.
3. Pienta, K. J., Redman, B., Hussain, M., Cummings, G., Esper, P. S., Appel, C., and Flaherty, L. E. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol., 12: 2005-2012, 1994.
4. Hudes, G., Obasaju, C., Chapman, A., Gallo, J., McAleer, C., and Greenberg, R. Phase I study of paclitaxel and estramustine: preliminary activity in hormone refractory prostate cancer. Semin. Oncol., 22 (Suppl. 6): 6-11, 1995.
5. Van Poppel, H., De Ridder, D., Elgamal, A. A., Van De Voorde, W., Werbrouck, P., Ackaert, P., Oyen, R., Pittomvils, G., Baert, L., and Members of the Belgian Uro-Oncological Study Group. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J. Urol., 154: 429-434, 1995.
6. Van De Voorde, W., Elgamal, A. A., Van Poppel, H. P., Verbeken, E. K., Baert, L. V., and Lauweryns, J. M. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy: a comparative study of radical prostatectomies. Cancer (Phila.), 74: 3164-3175, 1994.
7. Gunnarsson, P. O., Plym Forshell, G., Fritjofsson, Å., and Norlén, B. J. Plasma concentration of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt). Scand. J. Urol. Nephrol., 15: 201-206, 1981.
8. Hartley-Asp, B. Estramustine induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate, 5: 93-100, 1984.
9. 4 mouse cells and DU 145 human prostate carcinoma cells in vitro. Cancer Res., 48: 1842-1849, 1988.
10. Wang, M., Tew, K. D., and Stearns, M. E. Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine. Anticancer Res., 7: 1165-1172, 1987.
11. Eklöv, S., Nilsson, S., Larson, A., Björk, P., and Hartley-Asp, B. Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo. Prostate, 20: 43-50, 1992.
12. Dahllöf, B., Hartley-Asp, B., Billström, A., and Cabral, F. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res., 53: 4573-4581, 1993.
13. Laing, N., Hartley-Asp, B., Ranganathan, S., and Tew, K. D. The interaction of estramustine with microtubule proteins and with β-tubulin isotypes. Biochemistry, 36: 871-878, 1997.
14. Vallbo, C., Bergenheim, A. T., and Henriksson, R. Estramustine induces apoptosis in malignant human and rat glioma but not in normal brain tissue. Eur. J. Cancer, 31 (Suppl 5): 60, 1995.
15. Norlén, B. J., Andersson, S. B., Björk, P., Gunnarsson, P. O., and Fritjofsson, Å. Uptake of estramustine phosphate (Estracyt) metabolites in prostate cancer. J. Urol., 140: 1058-1062, 1988.
16. Flüchter, S. H., Nelde, H. J., Björk, P., Müntzing, J., and Bichler, K. H. Effect of treatment on the expression of estramustine-binding protein (EMBP) in prostatic cancer patients: an immunohistochemical study. Prostate, 14: 27-43, 1989.
17. Forsgren, B., Björk, P., Carlström, K., Gustafsson, J. Å., Pousette, Å., and Högberg, B. Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivative of estradiol-17β. Proc. Natl. Acad. Sci. USA, 76: 3149-3153, 1979.
18. Björk, P., Donn, F., Glad, C., Sundblad, G., Vestberg, M., and Kailand, T. Purification of estramustine-binding protein and production of monoclonal antibodies to its different components. Prostate, 27: 70-83, 1995.
19. Shiina, H., Sumi, H., Ishibe, T., and Usui, T. Study of estramustine binding protein: its relationship to androgen dependency and histological differentiation in human prostatic carcinoma tissue. Urol. Int., 52: 213-216, 1994.
20. Bergenheim, A. T., Gunnarsson, P. O., Edman, K., von Schoultz, E., Hariz, M. I., and Henriksson, R. Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans. Br. J. Cancer, 67: 358-361, 1993.
21. Fernö, M., Borg, Å., and Idvall, I. Estramustine binding site in human breast cancer biopsy samples. Its relation to estrogen and progesterone receptor levels, age and menopausal status. Eur. J. Cancer Clin. Oncol., 23: 1505-1510, 1987.
22. Bergh, J., Björk, P., Westlin, J-E., and Nilsson, S. Expression of an estramustine-binding associated protein in human lung cancer cell lines. Cancer Res., 48: 4615-4619, 1988.
23. Björk, P., Jönsson, U., and Andrén-Sandberg, Å. Binding sites for the cytotoxic metabolites of estramustine phosphate (Estracyt) in rat and human pancreas that are distinct from pancreatic estrogen-binding protein. Pancreas, 6: 77-89, 1991.
24. Shiina, H., Urakami, S., Shirakawa, H., Igawia, M., Ishibe, T., and Usui, T. Estramustine-binding protein in carcinoma and benign hyperplasia of the human prostate. Eur. Urol., 734: 1-7, 1995.
25. Forsgren, B., and Högberg, B. Binding of estramustine, a nitrogen mustard derivative of estradiol-17β, in cytosol from rat ventral prostate. Acta. Pharm. Suec., 15: 23-32, 1978.
26. Andersson, S. B., Lundgren, R., and Svensson, L. Gas chromatographic determination of four metabolites of estramustine phosphate on plasma. Acta. Pharm. Suec., 19: 1-10, 1982.
27. Gunnarsson, P. O., Andersson, S-B., Sandberg, A. A., and Ellman, M. Accumulation of estramustine and estromustine in adipose tissue of rats and humans. Cancer Chemother. Pharmacol., 28: 361-364, 1991.
28. Shiina, H., Igawa, M., and Ishibe, T. Clinical study on estramustine binding protein (EMBP) in human prostate. Prostate, 29: 169-176, 1996.
29. Speicher, L., Barone, L. R., Chapman, A. E., Hudes, G. R., Laing, N., Smith C. D., and Tew, K. D. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J. Natl. Cancer Inst., 86: 688-694, 1994.
30. Yang Chia-Ping, H., Shen, H., and Horwitz, S. B. Modulation of the function of P-glycoprotein by estramustine. J. Natl. Cancer Inst., 86: 723-725, 1994.
31. Batra, S. C., and Hartley-Asp, B. Synergistic effects of estramustine in combination with vinblastine or doxorubicin on prostatic tumor cells. 1st World Congress Basic Urol. Res., Rotterdam, 1995.